Entities / Company
aTyr Pharma.
company in San Diego, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 36
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
One to three months ago
-
Cantor Fitzgerald reiterated an Overweight rating for aTyr Pharma on August 20, 2025.Some support2 reports
-
Multiple legal appointments and JD degree completions were reported on August 11, 2026, involving several pharmaceutical companies.Some support1 report
-
aTyr Pharma disclosed insider trading to the SEC on August 8, 2026, coinciding with Freedom Capital raising its rating on the company and Paul Schimmel purchasing shares.Some support1 report
Gone quiet
No new reports in 90+ days-
Zeta, aTyr Pharma, and Vertical Aerospace are noted for being positioned in massive market sectors and utilizing transformative technology.Some support1 report
-
aTyr Pharma was added to the Russell Indexes on June 26, 2025.Speculative1 report
-
aTyr Pharma enrolled subjects at multiple centers globally, including Europe, for a clinical study.Some support2 reports
-
Martin Shkreli revealed a short position against aTyr Pharma on July 31, 2025, stating he believes the company's lead drug is ineffective.Some support1 report
-
aTyr Pharma announced its results from San Diego on August 8, 2025.Well supported3 reports
-
aTyr Pharma and MoonLake Immunotherapeutics are small-cap biotech stocks.Some support1 report
-
The stock price of aTyr Pharma was used as the exercise price for new employees.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around aTyr Pharma this week
News at the entities that move aTyr Pharma most-
FDA StructuralFDA approved a GSK drug and authorized a Roche blood test for eligibility, amidst estimates of 1.7M chronic HBV patients in the US.Moves aTyr Pharma
-
Freedom Capital Mentioned togetherFreedom Capital lowered Gentex's rating, while MarketBeat reported consensus ratings for the company, which is listed on Nasdaq.Moves aTyr Pharma
-
Nasdaq StructuralTNL Mediagene announced the resignation of board member Hiroto Kobayashi while maintaining Nasdaq compliance.Moves aTyr Pharma
-
SEC StructuralCboe Global Markets received SEC approvals for new contracts and extended its exclusive S&P license through 2051.Moves aTyr Pharma
-
San Diego Shared contextProPublica reported negligence concerning the leadership of the U.S. Pacific Fleet's Boxer ship in the San Diego region.Moves aTyr Pharma
Connections
The 7 strongest of 36, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
SEC Structural
aTyr Pharma was required to disclose insider trading activities to the SEC.
-
Alejandra Carvajal Structural
Alejandra Carvajal holds a chief legal officer role at aTyr Pharma.
-
FDA Structural
aTyr Pharma seeks and undergoes regulatory review by the FDA for drug approval.
-
Paul Schimmel Transactional
Paul Schimmel executed an insider purchase of shares in aTyr Pharma.
-
San Diego Shared context
aTyr Pharma is a biotech company based in and conducting operations within San Diego.
-
Freedom Capital Mentioned together
Freedom Capital provided a rating update on aTyr Pharma.
-
Nasdaq Structural
aTyr Pharma's shares are publicly traded on the Nasdaq exchange.
History
Events by the month they beganOctober 2026
1 eventAugust 2026
2 events- Multiple legal appointments and JD degree completions were reported on August 11, 2026, involving several pharmaceutical companies.
- aTyr Pharma disclosed insider trading to the SEC on August 8, 2026, coinciding with Freedom Capital raising its rating on the company and Paul Schimmel purchasing shares.
June 2026
8 events- Cantor Fitzgerald reiterated an Overweight rating for aTyr Pharma on August 20, 2025.
- Zeta, aTyr Pharma, and Vertical Aerospace are noted for being positioned in massive market sectors and utilizing transformative technology.
- aTyr Pharma was added to the Russell Indexes on June 26, 2025.
- aTyr Pharma enrolled subjects at multiple centers globally, including Europe, for a clinical study.
- Martin Shkreli revealed a short position against aTyr Pharma on July 31, 2025, stating he believes the company's lead drug is ineffective.
- aTyr Pharma announced its results from San Diego on August 8, 2025.
- aTyr Pharma and MoonLake Immunotherapeutics are small-cap biotech stocks.
- The stock price of aTyr Pharma was used as the exercise price for new employees.